Drug intelligence / Profile preview

Loymaxi

Development stage
Unknown
Lead developer
Lloyd Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

Loymaxi is a branded generic fixed-dose combination product marketed by Lloyd Healthcare, an Indian pharmaceutical company, for use in orthopedic and musculoskeletal care. The formulation typically contains methylcobalamin (1500 mcg), alpha-lipoic acid (100 mg), pyridoxine (3 mg), and folic acid (1.5 mg). It is primarily indicated for the management of peripheral neuropathy, radiculopathy, and other musculoskeletal conditions where nerve health and oxidative stress are concerns. Methylcobalamin, a bioactive form of Vitamin B12, supports nerve regeneration and myelin sheath maintenance. Alpha-lipoic acid acts as a potent antioxidant to protect neural tissues from oxidative damage. Pyridoxine and folic acid serve as essential cofactors for metabolic processes and DNA synthesis. Loymaxi is commercially available in India as an oral formulation.

Brand names
Loymaxi
02

Targets

1C metabolism (One-carbon metabolism)PDXK (Pyridoxal kinase)Nucleotide synth (Nucleotide synthesis enzymes)

Beyond the preview

Go deeper on Loymaxi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Loymaxi.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call